Contributing Author
Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.
In recent years, therapeutic capabilities in oncology have grown dramatically, with a vast array of advanced treatments progressing through clinical trials and onto the market. However, there has been a lag between the development of promising precision treatments and the identification, development and implementation of biomarkers that identify patients most likely to benefit from them. In fact, in a survey of oncology developers, more than half of respondents (53%) reported that difficulty identifying predictive biomarkers limited the utility of their therapeutic approach.
The field of oncology is experiencing a proliferation of cancer therapies. In 2024 alone, the U.S. Food and Drug Administration (FDA) issued more than 60 oncology approvals, including 11 for first-in-class therapeutics.1 This diverse array of increasingly specialized treatments is reshaping the oncology market and ushering in a more diversified era of cancer treatment. Moreover, the landscape has shifted from SoC chemotherapies and radiation therapies to combinations of these with agents that include but are not limited to molecular targeted treatments and radiopharmaceuticals with synergistic effects.